Rubin Jonathan's most recent trade in Robinhood Markets Inc - Ordinary Shares - Class A was a trade of 312 Class A Common Stock done . Disclosure was reported to the exchange on June 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 312 | 16,158 | - | - | Class A Common Stock | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2025 | 3,202 | 3,202 | - | - | Restricted Stock Units | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2025 | 2,522 | 0 | - | - | Restricted Stock Units | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2025 | 2,522 | 18,368 | - | - | Class A Common Stock | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2025 | 4,528 | 20,374 | - | - | Class A Common Stock | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2025 | 4,528 | 0 | - | - | Restricted Stock Units | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2025 | 2,521 | 16,548 | - | - | Class A Common Stock | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2025 | 2,521 | 2,522 | - | - | Restricted Stock Units | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 702 | 21,076 | - | - | Class A Common Stock | |
| Supernus Pharmaceuticals Inc | Jonathan Rubin | SVP, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.05 per share. | 05 Mar 2025 | 577 | 10,212 (0%) | 0% | 33.1 | 19,070 | Common Stock |
| Supernus Pharmaceuticals Inc | Jonathan Rubin | SVP, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.05 per share. | 05 Mar 2025 | 577 | 9,635 (0%) | 0% | 33.1 | 19,070 | Common Stock |
| Supernus Pharmaceuticals Inc | Jonathan Rubin | SVP, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.05 per share. | 05 Mar 2025 | 314 | 10,789 (0%) | 0% | 33.1 | 10,378 | Common Stock |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 4,528 | 4,528 | - | - | Restricted Stock Units | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 4,528 | 20,374 | - | - | Class A Common Stock | |
| Supernus Pharmaceuticals Inc | Jonathan Rubin | SVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 1,875 | 0 | - | - | Performance Share Units | |
| Supernus Pharmaceuticals Inc | Jonathan Rubin | SVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 1,875 | 8,780 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Jonathan Rubin | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 1,250 | 9,853 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Jonathan Rubin | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 1,250 | 11,103 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Jonathan Rubin | SVP, Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Feb 2025 | 1,250 | 2,500 | - | - | Restricted Stock Unit | |
| Supernus Pharmaceuticals Inc | Jonathan Rubin | SVP, Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Feb 2025 | 1,250 | 3,750 | - | - | Restricted Stock Unit | |
| Supernus Pharmaceuticals Inc | Jonathan Rubin | SVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 39.15 per share. | 21 Feb 2025 | 927 | 7,853 (0%) | 0% | 39.1 | 36,292 | Common Stock |
| Supernus Pharmaceuticals Inc | Jonathan Rubin | SVP, Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Feb 2025 | 750 | 750 | - | - | Restricted Stock Unit | |
| Supernus Pharmaceuticals Inc | Jonathan Rubin | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 750 | 8,603 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Jonathan Rubin | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 20,000 | 20,000 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Jonathan Rubin | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 4,500 | 4,500 | - | - | Restricted Stock Unit | |
| Supernus Pharmaceuticals Inc | Jonathan Rubin | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 1,875 | 1,875 | - | - | Performance Share Units | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 2,521 | 5,043 | - | - | Restricted Stock Units | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 2,521 | 19,152 | - | - | Class A Common Stock | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Grant, award, or other acquisition of securities at price $ 37.26 per share. | 31 Dec 2024 | 785 | 16,631 | - | 37.3 | 29,249 | Class A Common Stock |
| Supernus Pharmaceuticals Inc | Rubin Jonathan | SVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2024 | 1,875 | 7,416 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Jonathan Rubin | SVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2024 | 1,875 | 0 | - | - | Performance Share Unit | |
| Supernus Pharmaceuticals Inc | Rubin Jonathan | SVP, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.59 per share. | 27 Dec 2024 | 821 | 6,595 (0%) | 0% | 35.6 | 29,219 | Common Stock |
| Supernus Pharmaceuticals Inc | Jonathan Rubin | SVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2024 | 750 | 5,822 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Jonathan Rubin | SVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2024 | 750 | 0 | - | - | Performance Share Unit | |
| Supernus Pharmaceuticals Inc | Rubin Jonathan | SVP, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.59 per share. | 27 Dec 2024 | 281 | 5,541 (0%) | 0% | 35.6 | 10,001 | Common Stock |
| Supernus Pharmaceuticals Inc | Jonathan Rubin | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2024 | 1,875 | 1,875 | - | - | Performance Share Unit | |
| Supernus Pharmaceuticals Inc | Rubin Jonathan | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2024 | 750 | 750 | - | - | Performance Share Unit | |
| Amazon | Jonathan J. Rubinstein | Director | Sale of securities on an exchange or to another person at price $ 229.85 per share. | 09 Dec 2024 | 4,351 | 88,203 (0%) | 0% | 229.8 | 1,000,077 | Common Stock, par value $.01 per share |
| Amazon | Jonathan J. Rubinstein | Director | Sale of securities on an exchange or to another person at price $ 219.85 per share. | 04 Dec 2024 | 4,549 | 92,554 (0%) | 0% | 219.9 | 1,000,098 | Common Stock, par value $.01 per share |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2024 | 4,528 | 9,056 | - | - | Restricted Stock Units | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2024 | 4,528 | 28,757 | - | - | Class A Common Stock | |
| Amazon | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2024 | 2,473 | 97,103 (0%) | 0% | 0 | Common Stock, par value $.01 per share | |
| Amazon | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2024 | 2,473 | 2,473 | - | - | Restricted Stock Unit Award | |
| Amazon | Jonathan J. Rubinstein | Director | Sale of securities on an exchange or to another person at price $ 209.85 per share. | 07 Nov 2024 | 4,766 | 94,630 (0%) | 0% | 209.8 | 1,000,145 | Common Stock, par value $.01 per share |
| Amazon | Jonathan J. Rubinstein | Director | Sale of securities on an exchange or to another person at price $ 199.85 per share. | 01 Nov 2024 | 5,004 | 99,396 (0%) | 0% | 199.8 | 1,000,049 | Common Stock, par value $.01 per share |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2024 | 2,521 | 7,564 | - | - | Restricted Stock Units | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2024 | 2,521 | 24,229 | - | - | Class A Common Stock | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2024 | 1,334 | 21,708 | - | - | Class A Common Stock | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 4,528 | 20,374 | - | - | Class A Common Stock | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 4,528 | 13,584 | - | - | Restricted Stock Units | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2024 | 1,381 | 39,091 | - | - | Class A Common Stock | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 10,085 | 10,085 | - | - | Restricted Stock Units | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jun 2024 | 5,625 | 37,710 | - | - | Class A Common Stock | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jun 2024 | 5,625 | 0 | - | - | Restricted Stock Units | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2024 | 4,528 | 18,112 | - | - | Restricted Stock Units | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2024 | 4,528 | 32,085 | - | - | Class A Common Stock | |
| Amazon | Jonathan J. Rubinstein | Director | Sale of securities on an exchange or to another person at price $ 190.00 per share. | 09 May 2024 | 5,264 | 104,400 (0%) | 0% | 190 | 1,000,160 | Common Stock, par value $.01 per share |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 5,625 | 5,625 | - | - | Restricted Stock Units | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 5,625 | 27,557 | - | - | Class A Common Stock | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2024 | 1,558 | 21,932 | - | - | Class A Common Stock | |
| Amazon | Jonathan J. Rubinstein | Director | Sale of securities on an exchange or to another person at price $ 180.00 per share. | 04 Mar 2024 | 5,556 | 109,664 (0%) | 0% | 180 | 1,000,080 | Common Stock, par value $.01 per share |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 4,528 | 22,640 | - | - | Restricted Stock Units | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 4,528 | 20,374 | - | - | Class A Common Stock | |
| Supernus Pharmaceuticals Inc | Rubin Jonathan | SVP, Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 23 Feb 2024 | 1,250 | 3,750 | - | - | Restricted Stock Unit | |
| Supernus Pharmaceuticals Inc | Rubin Jonathan | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 1,250 | 5,208 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Rubin Jonathan | SVP, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.06 per share. | 23 Feb 2024 | 567 | 4,641 (0%) | 0% | 29.1 | 16,477 | Common Stock |
| Supernus Pharmaceuticals Inc | Rubin Jonathan | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 25,000 | 25,000 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Jonathan Rubin | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 5,000 | 5,000 | - | - | Restricted Stock Unit | |
| Supernus Pharmaceuticals Inc | Rubin Jonathan | SVP, Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Feb 2024 | 750 | 1,500 | - | - | Restricted Stock Unit | |
| Supernus Pharmaceuticals Inc | Rubin Jonathan | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 750 | 4,261 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Jonathan Rubin | SVP, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.94 per share. | 22 Feb 2024 | 303 | 3,958 (0%) | 0% | 27.9 | 8,466 | Common Stock |
| Amazon | J. Jonathan Rubinstein | Director | Sale of securities on an exchange or to another person at price $ 171.00 per share. | 09 Feb 2024 | 12,133 | 115,220 (0%) | 0% | 171 | 2,074,743 | Common Stock, par value $.01 per share |
| Robinhood Markets Inc - Or... | Rubinstein J. Jonathan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2023 | 5,625 | 11,250 | - | - | Restricted Stock Units | |
| Robinhood Markets Inc - Or... | J. Jonathan Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2023 | 5,625 | 15,846 | - | - | Class A Common Stock | |
| Robinhood Markets Inc - Or... | Jonathan Rubinstein J. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2023 | 2,462 | 10,221 | - | - | Class A Common Stock | |
| Supernus Pharmaceuticals Inc | Jonathan Rubin | Sr. VP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2023 | 600 | 0 | - | - | Performance Share Unit | |
| Supernus Pharmaceuticals Inc | Jonathan Rubin | Sr. VP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2023 | 600 | 3,447 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Jonathan Rubin | Sr. VP, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.66 per share. | 22 Dec 2023 | 204 | 3,243 (0%) | 0% | 27.7 | 5,643 | Common Stock |
| Supernus Pharmaceuticals Inc | Rubin Jonathan | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2023 | 600 | 600 | - | - | Performance Share Unit | |
| Robinhood Markets Inc - Or... | J. Rubinstein Jonathan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2023 | 4,528 | 7,759 | - | - | Class A Common Stock | |
| Robinhood Markets Inc - Or... | J. Rubinstein Jonathan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2023 | 4,528 | 27,168 | - | - | Restricted Stock Units | |
| Amazon | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2023 | 2,473 | 127,353 (0%) | 0% | 0 | Common Stock, par value $.01 per share | |
| Amazon | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2023 | 2,473 | 4,946 | - | - | Restricted Stock Unit Award | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2023 | 3,143 | 10,902 | - | - | Class A Common Stock | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 22,500 | 22,500 | - | - | Restricted Stock Units | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2023 | 4,528 | 7,759 | - | - | Class A Common Stock | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2023 | 4,528 | 36,223 | - | - | Restricted Stock Units | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 3,231 | 3,231 | - | - | Class A Common Stock | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 4,528 | 4,528 | - | - | Class A Common Stock | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 4,528 | 40,751 | - | - | Restricted Stock Units | |
| Supernus Pharmaceuticals Inc | Jonathan Rubin | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 20,000 | 20,000 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Jonathan Rubin | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 5,000 | 5,000 | - | - | Restricted Stock Units | |
| Supernus Pharmaceuticals Inc | Jonathan Rubin | SVP, Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Feb 2023 | 750 | 2,250 | - | - | Restricted Stock Units | |
| Supernus Pharmaceuticals Inc | Jonathan Rubin | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2023 | 750 | 2,497 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Jonathan Rubin | SVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2023 | 1,500 | 1,500 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Jonathan Rubin | SVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2023 | 1,500 | 0 | - | - | Performance Share Unit | |
| Supernus Pharmaceuticals Inc | Jonathan Rubin | Sr. VP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2023 | 1,500 | 1,500 | - | - | Performance Share Unit | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2022 | 3,854 | 3,854 | - | - | Restricted Stock Units | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2022 | 4,528 | 4,528 | - | - | Class A Common Stock | |
| Robinhood Markets Inc - Or... | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2022 | 4,528 | 45,279 | - | - | Restricted Stock Units | |
| Amazon | Jonathan J. Rubinstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2022 | 3,440 | 0 | - | - | Restricted Stock Unit Award |